Periprosthetic Joint Infection Bubble Study (PJI)
2026年7月29日 更新者：Thomas Jefferson University
Using Ultrasound and Microbubbles to Augment Antibiotic Efficiency Against Periprosthetic Joint Infections
Patients with an infected knee replacement will receive their standard of care surgical treatment of the infection, with and without additional ultrasound microbubble treatment (randomly divided 50/50 in the active and control groups).
Subjects in the active group will receive a local bolus injection of antibiotics and ultrasound-active microbubbles within 24 hours of their revision surgery.
The fundamental hypothesis is that a decrease in re-infection rates of at least 24% can be achieved in the active group relative to controls.
研究概览
研究类型
介入性
注册 (估计的)
100
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19107
- 招聘中
- Thomas Jefferson University/Rothman Institute
-
接触：
- Edsel Mangubat, MBA, MSN, RN
- 电话号码：267-386-5480
- 邮箱：Edsel.mangubat@jefferson.edu
-
首席研究员：
- Lauren Delaney, PhD
-
Pittsburgh、Pennsylvania、美国、15213
- 尚未招聘
- University of Pittsburgh Medical Center (UPMC)
-
首席研究员：
- Kenneth Urish, MD, PhD
-
接触：
- Dana Farrell
- 电话号码：412-641-3156
- 邮箱：djf52@pitt.edu
-
-
Texas
-
Dallas、Texas、美国、75390
- 尚未招聘
- UT Southwestern Medical Center
-
接触：
- Jonathan Thompson
- 电话号码：214-645-1620
- 邮箱：jonathan.thompson@utsouthwestern.edu
-
首席研究员：
- Antonia Chen, MD
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Be at least 18 years of age
- Be medically stable
- If female of child-bearing potential, must have a negative pregnancy test
- Be conscious and able to comply with study procedures
- Have read and signed the IRB-approved Informed Consent form for participating in the study
- For Cohort 1, be scheduled for one- or two-stage exchange arthroplasty revision surgery for PJI of the knee
- For Cohort 2, be scheduled for DAIR revision surgery for PJI of the knee
Exclusion Criteria:
- Females who are pregnant or nursing
- Patients currently on chemotherapy requiring systemic infusion treatment
- Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
- Patients with a history of anaphylactic allergy to perflutren or any other components of Definity
- Patients with a history of failed one- or two-stage revision for infection
- Patients for which placement of a surgical drain is contraindicated
- Patients in protected classes (e.g., prisoners)
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Cohort 1 Exchange anthroplasty - experimental group
The experimental group will undergo an US exam within 24 hours following the revision surgery with a Logiq E10 scanner (GE HealthCare), with a B-mode scan to acquire the radiofrequency (RF) data for the quantitative H-scan analysis, and a contrast-enhanced US (CEUS) scan to perform the UTMD therapy.
Following the B-mode scan, the wound site will be sterilized and subjects will receive a localized injection of antibiotics (determined by the orthopaedic surgeon based on intra-operative cultures) and Definity microbubbles to perform the UTMD therapy using commercially-available flash-replenishment sequences.
|
A combination of Definity microbubbles and clinically-relevant antibiotics will in injected into the intraarticular space of the knee the day after revision surgery.
Ultrasound will be used to rupture the microbubbles to enhance antibiotic activity.
其他名称：
|
|
实验性的：Cohort 2 Debridement, antibiotics, and implant retention (DAIR) revision surgery - experimental
The experimental group will undergo an US exam within 24 hours following the revision surgery with a Logiq E10 scanner (GE HealthCare), with a B-mode scan to acquire the radiofrequency (RF) data for the quantitative H-scan analysis, and a contrast-enhanced US (CEUS) scan to perform the UTMD therapy.
Following the B-mode scan, the wound site will be sterilized and subjects will receive a localized injection of antibiotics (determined by the orthopaedic surgeon based on intra-operative cultures) and Definity microbubbles to perform the UTMD therapy using commercially-available flash-replenishment sequences.
|
A combination of Definity microbubbles and clinically-relevant antibiotics will in injected into the intraarticular space of the knee the day after revision surgery.
Ultrasound will be used to rupture the microbubbles to enhance antibiotic activity.
其他名称：
|
|
无干预：Cohort 1 Exchange anthroplasty - control group
The control group will undergo clinical standard of care with no therapeutic interventions from the study team, only the collection of the wound exudate from the wound drain.
|
|
|
无干预：Cohort 2 Debridement, antibiotics, and implant retention (DAIR) revision surgery - control
The control group will undergo clinical standard of care with no therapeutic interventions from the study team, only the collection of the wound exudate from the wound drain.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Re-Infection Rate
大体时间：2 years
|
Rate of re-infection within 2 years post-intervention
|
2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to Re-Infection
大体时间：2 years
|
Time between initial intervention and presentation with re-infection
|
2 years
|
|
Bacterial Debris
大体时间：72 hours
|
Measurement of bacterial debris present in would exudate from drains
|
72 hours
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年6月30日
初级完成 (估计的)
2028年6月1日
研究完成 (估计的)
2030年6月1日
研究注册日期
首次提交
2026年5月14日
首先提交符合 QC 标准的
2026年5月14日
首次发布 (实际的)
2026年5月20日
研究记录更新
最后更新发布 (实际的)
2026年7月31日
上次提交的符合 QC 标准的更新
2026年7月29日
最后验证
2026年7月1日
更多信息
与本研究相关的术语
其他研究编号
- 2025-0492
- 1R01AI187384-01 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
未定
IPD 计划说明
De-identified data will be shared upon request
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.